(Q46234832)

English

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

scientific article published in March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Frank M Ruemmele

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Alain Lachaux

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Jean-Pierre Cézard

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Alain Morali

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Chantal Maurage

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Jean-Louis Giniès

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Sheila Viola

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Olivier Goulet

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Thierry Lamireau

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Michèle Scaillon

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Anne Breton

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Jacques Sarles

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Groupe Francophone d'Hépatologie, Gastroentérologie et Nutrition Pédiatrique

13

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

15

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

388-394

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

Inflammatory bowel disease: etiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

The fundamental basis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

The immunological and genetic basis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

New links to the pathogenesis of Crohn disease provided by genome-wide association scans

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

A new look at Crohn's disease: breakdown of the mucosal antibacterial defense

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Is Crohn's disease due to defective immunity?

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Biologic therapy of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

A simple index of Crohn's-disease activity

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Incidence of inflammatory bowel disease in northern France (1988-1990).

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Use of infliximab in the treatment of Crohn's disease in children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20788

21 January 2018

Identifiers

10.1002/IBD.20788

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19023899

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46234832&oldid=2101729553"